Stachydrine: A Systematic Review of Its Multi-Targeted Therapeutic Potential in Cardiovascular, Oncology, Renal, Gynecological, and Inflammatory Disorders

Background: Stachydrine, a principal bioactive alkaloid derived from Leonurus japonicus (motherwort), has attracted significant interest due to its diverse pharmacological activities and nutritional relevance. This systematic review synthesizes current evidence on its therapeutic potential across multiple organ systems. Stachydrine core pharmacological activities are: Cardiovascular protection: Stachydrine mitigates myocardial ischemia/reperfusion injury by scavenging free radicals, reducing myocardial biomarkers (CK, LDH, cTnT), and enhancing nitric oxide (NO) production. It attenuates pathological ventricular remodeling by suppressing ROS-mediated activation of NF-κB and improves cardiac calcium handling by protecting sarcoplasmic reticulum function. Antitumor effects: In cancers (e.g. hepatocellular carcinoma, breast cancer, colorectal cancer), stachydrine inhibits tumor proliferation, metastasis, and chemoresistance by targeting pathways such as TGF-β/Smad, PI3K/Akt/mTOR, and JAK2/STAT3. It also modulates the tumor microenvironment by reprogramming tumor-associated macrophages. Renoprotective actions: It ameliorates drug-induced renal fibrosis by suppressing tubular cell apoptosis via downregulation of caspase-9/caspase-12 and inhibiting inflammatory cytokine release. Uteroprotective benefits: Stachydrine regulates uterine hemorrhage by balancing Th1/Th2/Th17/Treg immune homeostasis and modulating endothelial function (e.g. NO and endothelin-1 levels), while enhancing uterine smooth muscle contractility. Antioxidant mechanisms: It reduces oxidative stress via ROS scavenging and NOX2 pathway inhibition, thereby protecting cardiovascular and neuronal tissues. Anti-inflammatory properties: Through modulation of NF-κB, JAK2/STAT3, and AMPK/SIRT1 pathways, stachydrine alleviates acute and chronic inflammation in models ranging from arthritis to neuroinflammation. Conclusion: This review comprehensively documents stachydrine’s multi-targeted and multi-organ therapeutic potential, driven by its pleiotropic mechanisms. It provides a robust foundation for clinical translation in cardiovascular diseases, cancer, renal disorders, gynecological conditions, and inflammation-associated pathologies. Future research should prioritize high-quality clinical trials and synergistic drug-combination strategies to harness its therapeutic efficacy fully.